FILTER

Refine your search with the following facets to narrow down your results.

226 Current news of Evotec

Jörn Aldag resigns as CEO of Evotec AG

15-Dec-2008 - Evotec AG announced that Jörn Aldag will resign from his position as President & Chief Executive Officer of Evotec. The resignation will be effective as of December 31, 2008. Dr Mario Polywka, Chief Operating Officer, and Dr Klaus Maleck, Chief Financial Officer, will jointly lead the Company ...

CNS drugs Evotec

Evotec Announces Three-Year Drug Discovery Collaboration With Novartis

05-Dec-2008 - Evotec AG announced the start of a research collaboration with Novartis to identify and develop novel small molecule therapeutics. The collaboration will run for an initial period of three years. Evotec will apply its drug discovery platform in combination with its disease biology expertise to ...

biology drug discovery collaborations Evotec +3

Evotec Reports Phase I Safety Data from Tyramine Interaction Study with EVT 302

28-Oct-2008 - Evotec AG announced encouraging results of a Phase I safety study investigating the potential interaction of EVT 302, a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B) in development for smoking cessation, with tyramine. The study was undertaken to determine potential ...

clinical trials Evotec inhibitors +2

Evotec-RSIL Ltd announces two key library synthesis collaborations and celebrates its first full year of operations

24-Oct-2008 - Evotec-RSIL Ltd announced two new contracts with global pharmaceutical companies for the synthesis and supply of compound libraries. These follow a successful year of operations which has seen them sign collaborations with a total of five companies. In the latest deals Evotec-RSIL Ltd has signed ...

biotechnology collaborations compound libraries +6

Evotec Reports Start of Phase II Proof-of-Concept Quit Rate Study with EVT 302 and Results of Craving Study

12-Sep-2008 - Evotec AG announced the start of the Phase II proof-of-concept study, investigating the effect of EVT 302 on the quit rate of patients who want to stop smoking. The Company also provided an analysis of the results of its exploratory Phase II craving study of the same compound. EVT 302 is a ...

Evotec inhibitors smoking cessation

Evotec Announces Initiation of Phase I Clinical Trial of VR1 Antagonist under Partnership with Pfizer Inc.

05-Aug-2008 - Evotec AG announced that dose escalation studies for a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist is being progressed by Pfizer Inc. under the collaboration with Evotec. The Phase I study is a randomised, double-blind and placebo-controlled single ascending ...

clinical trials diseases Evotec +5

DIREVO announces transfer of patents from Evotec

11-Jul-2008 - DIREVO Biotech AG announced that it has entered into an agreement with Evotec under which Evotec will transfer certain patents to DIREVO that are currently licensed by DIREVO. Such patents protect key components of DIREVO's unique and proven protein/strain engineering platform. Using this ...

AstraZeneca Evotec MedImmune +3

Evotec's EVT 101 well tolerated in four week higher repeat dose safety study

07-Jul-2008 - Evotec AG announced top-line results of a double-blind, 4-week Phase Ib study with EVT 101, an orally active NR2B-subtype selective antagonist of NMDA receptors with potential in Alzheimer's disease, neuropathic pain and other indications. The study showed in both young and elderly subjects that ...

Alzheimer's disease dosing Evotec +1

Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis

11-Jan-2008 - Evotec AG provided further details on its planned NASDAQ listing in the context of the anticipated acquisition of Renovis Inc. Evotec AG has filed a registration statement on Form F-4 to register with the US Securities and Exchange Commission (SEC) the Evotec AG ordinary shares. These shares ...

Evotec

Evotec Completes Divesture of Chemical Development

04-Dec-2007 - Evotec AG announced that it has completed the sale of its Chemical Development Business to Aptuit, Inc. for a total consideration of £ 31.5 million (approx. EUR 44 million) effective November 30, 2007. According to the company, this divestiture allows Evotec to focus even more on its strategy ...

cooperations Evotec